Insider · CIK 0002042634
YK Bioventures Opportunities GP I, LLC
Files at CERO (CERO THERAPEUTICS HOLDINGS, INC.). First filing Nov 14, 2024, latest Dec 13, 2024.
YK Bioventures Opportunities GP I, LLC files SEC Form 4 as 10% owner at CERO (CERO THERAPEUTICS HOLDINGS, INC.). Since Nov 14, 2024, YK Bioventures Opportunities GP I, LLC has reported 0 open-market buys worth $0 and 3 open-market sells worth $1.1M, the latest filed on Dec 13, 2024.
A track record needs three past buys with six months of prices behind them; YK Bioventures Opportunities GP I, LLC has 0, so none is measured yet.
The newest scored trade: sold $400k of CERO on Dec 11, 2024, filed Dec 13, 2024, scored 38 (weak).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CERO: CERO THERAPEUTICS HOLDINGS, INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | CEROsell CERO THERAPEUTICS HOLDINGS, INC. | $400k 5,957,250 shares | -31% | - | |
| 33Weak | CEROsell CERO THERAPEUTICS HOLDINGS, INC. | $383k 3,658,364 shares | -16% | - | |
| 31Weak | CEROsell CERO THERAPEUTICS HOLDINGS, INC. | $325k 3,250,000 shares | -13% | - |
Transactions
Every row this insider has filed, 7 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 11, 2024 | CERO CERO THERAPEUTICS HOLDINGS, INC. | SOpen-market sale Common Stockindirect: By YK Bioventures Opportunities Fund I, L.P. | -1,343,801 | $0.08 | $108k | 17,618,618 | Dec 13, 2024 |
| Dec 12, 2024 | CERO CERO THERAPEUTICS HOLDINGS, INC. | SOpen-market sale Common Stockindirect: By YK Bioventures Opportunities Fund I, L.P. | -1,614,541 | $0.07 | $113k | 16,004,077 | Dec 13, 2024 |
| Dec 13, 2024 | CERO CERO THERAPEUTICS HOLDINGS, INC. | SOpen-market sale Common Stockindirect: By YK Bioventures Opportunities Fund I, L.P. | -2,998,908 | $0.06 | $180k | 13,005,169 | Dec 13, 2024 |
| Dec 6, 2024 | CERO CERO THERAPEUTICS HOLDINGS, INC. | SOpen-market sale Common Stockindirect: By YK Bioventures Opportunities Fund I, L.P. | -1,236,874 | $0.12 | $148k | 21,383,909 | Dec 10, 2024 |
| Dec 9, 2024 | CERO CERO THERAPEUTICS HOLDINGS, INC. | SOpen-market sale Common Stockindirect: By YK Bioventures Opportunities Fund I, L.P. | -850,543 | $0.11 | $94k | 20,533,366 | Dec 10, 2024 |
| Dec 10, 2024 | CERO CERO THERAPEUTICS HOLDINGS, INC. | SOpen-market sale Common Stockindirect: By YK Bioventures Opportunities Fund I, L.P. | -1,570,947 | $0.09 | $141k | 18,962,419 | Dec 10, 2024 |
| Oct 10, 2024 | CERO CERO THERAPEUTICS HOLDINGS, INC. | SOpen-market sale Common Stockindirect: By YK Bioventures Opportunities Fund I, L.P. | -3,250,000 | $0.10 | $325k | 22,620,783 | Nov 14, 2024 |
Questions about YK Bioventures Opportunities GP I, LLC
Answered from the filings on this page, as of the latest one.
Is YK Bioventures Opportunities GP I, LLC buying or selling?
Not in the last 12 months. YK Bioventures Opportunities GP I, LLC's latest open-market trade on SEC Form 4 was sold $400k of CERO on Dec 11, 2024.
How did YK Bioventures Opportunities GP I, LLC's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and YK Bioventures Opportunities GP I, LLC has 0.
Where does YK Bioventures Opportunities GP I, LLC file Form 4?
YK Bioventures Opportunities GP I, LLC has filed Form 4 at CERO (CERO THERAPEUTICS HOLDINGS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.